Print this article
- 04/14/2022

KeyPlants ships first-of-its-kind vaccine manufacturing facility to Africa

Chimica Oggi-Chemistry Today


Stockholm, Sweden – KeyPlants, a leading provider of innovative life science facilities and PODs, announced today that it has shipped a first-of-its-kind vaccine manufacturing filling facility to Senegal in West Africa. KeyPlants successfully completed and shipped the facility in less than 8 months. After the facility is installed and becomes fully operational later in 2022, it will be the only regional manufacturing hub on the continent outside of South Africa capable of producing finished COVID-19 and other life-saving vaccines.


The shipment of this advanced facility is an important step towards realizing the vision of Project MADIBA, led by Institut Pasteur de Dakar (IPD), a non-profit foundation concerned with promoting public health and well-being in Senegal and throughout Africa. The project enjoys strong support from the government of Senegal, Africa CDC, WHO, CEPI and other partners and is supported by a global collaboration of funders and companies. These include KeyPlants and MEDInstill, which provides the novel vaccine manufacturing equipment utilized in the facility.


With the capacity to produce up to 300 million COVID-19 vaccine doses annually, Project MADIBA will revolutionize access to vaccines in Africa and implement a safe, financially sustainable, and autonomous infrastructure to secure vaccine access and equity for Africa.


Due to the facility’s multi-suite drug substance and fill-finish capabilities, Project MADIBA has the flexibility to facilitate the manufacture of additional therapeutics beyond mRNA vaccines and meet changing global health needs. Additionally, the portable and prefabricated design of the facility means that it is well equipped to scale-up or scale-out in line with the evolving needs of the local community.


The African Union and Africa CDC has identified vaccine manufacturing as a priority to address vaccine inequity to the continent, setting a target to manufacture 60% of African vaccine supply by 2040 and vaccine autonomy by 2060. Project MADIBA is a critical first step in achieving this goal, with this facility to serve as a blueprint for future vaccine manufacturing facilities to be built across Africa.


Dr. Amadou Sall, Director of Institut Pasteur de Dakar, commented: “Over a year after lifesaving COVID-19 vaccines were made broadly available to high-income countries, only 15 percent of Africa has been fully immunized. Against this backdrop, IPD remains focused on our vision to build and operate a vaccine manufacturing facility in Senegal that can produce vaccines for Africa as soon as possible.”


Jörgen Harrysson, CEO of KeyPlants, said: “We are proud to leverage our extensive experience and expertise in modular facilities and off-site manufacturing to drive forward this important project. By doing so, we will help provide crucial access to lifesaving therapeutics for the African population.”


Daniel Py, CEO and Founder of MEDInstill, added: “With the adoption of MEDInstill’s technology, Project MADIBA will be both transformative and disruptive in the pharma and biopharma space by delivering vaccines to those in need at an unmatched safety level.”


For further information, please contact:


Marija Mladenovic, Communications


About KeyPlants

KeyPlants, headquartered in Stockholm, Sweden, is a leader in the clean room manufacturing space for the life science industry, having executed 100+ projects globally. Our customers benefit from KeyPlants’ vast experience and expertise, resulting in 30-50% shorter timelines and increased predictability with regards to schedule, cost, and quality. KeyPlants deliver PODs and turnkey facilities including process equipment, utilities, and digital solutions.


About IPD

The Institut Pasteur de Dakar (IPD) is a non-profit public interest foundation located in Senegal with the mission to contribute to public health and well-being in Sénégal and Africa by conducting research, providing training and education, sharing scientific knowledge, and advancing vaccine production. Since its founding in 1896, IPD has been at the forefront of the fight against infectious diseases in West Africa. IPD is one of the four WHO prequalified manufacturers to supply yellow fever vaccine to UN’s Agencies.


Follow IPD via @PasteurDakar and LinkedIn.


About MEDInstill

MEDInstill have designed and developed its proprietary INTACT™ technologies to deliver innovative sterile liquid filling, multiple-dose dispensing, transfer, and packaging solutions across several industry segments to address the challenges of achieving consistent sterile results. All INTACT™ transfer devices are fully closed, prevent contact of the product or process with the environment, and solve some of the toughest and most costly problems faced by the pharmaceutical, biotechnology, healthcare, food and nutrition, and cosmetic industries. The INTACT™ product line includes connectors, environment independent filling lines, and dispensing valves.